Bio Path Holdings Stock Number Of Employees
| BPTH Stock | USD 0.80 0.02 2.44% |
Bio Path Holdings fundamentals help investors to digest information that contributes to Bio Path's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Path's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Path stock.
Bio | Number Of Employees |
Bio Path Holdings Company Number Of Employees Analysis
Bio Path's Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Current Bio Path Number Of Employees | 10 |
Most of Bio Path's fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Path Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bio Number Of Employees Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Path is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Number Of Employees. Since Bio Path's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Path's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Path's interrelated accounts and indicators.
Click cells to compare fundamentals
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
| Competition |
Based on the recorded statements, Bio Path Holdings is currently employing 10.0 people. This is 99.91% lower than that of the Biotechnology sector and 98.13% lower than that of the Health Care industry. The number of employees for all United States stocks is 99.95% higher than that of the company.
Bio Number Of Employees Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Path's direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics of similar companies.Bio Path is currently under evaluation in number of employees category among its peers.
Bio Fundamentals
| Return On Equity | -3.66 | ||||
| Return On Asset | -1.4 | ||||
| Current Valuation | 2.93 M | ||||
| Shares Outstanding | 4.31 M | ||||
| Shares Owned By Institutions | 1.08 % | ||||
| Number Of Shares Shorted | 77.76 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (15.76 M) | ||||
| Net Income | (16.08 M) | ||||
| Cash And Equivalents | 17.02 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 113 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.57 X | ||||
| Book Value Per Share | 0.71 X | ||||
| Cash Flow From Operations | (11.54 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (8.34) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 3.47 M | ||||
| Total Asset | 3.22 M | ||||
| Retained Earnings | (107.61 M) | ||||
| Working Capital | 1.14 M | ||||
| Current Asset | 9.59 M | ||||
| Current Liabilities | 937 K | ||||
| Net Asset | 3.22 M |
About Bio Path Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Path Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out Bio Path Piotroski F Score and Bio Path Altman Z Score analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.